Introduction to type 2 diabetes
The prevalence of type 2 diabetes is growing at an alarming rate with past forecasts being exceeded years before predicted. In 2017, over 420 million people were living with diabetes and this number is expected to continue rising with the increasing levels of obesity seen in populations around the world.
However, effective treatment alternatives are available to reduce the burden and manage the risk of complications of type 2 diabetes. Explore the type 2 diabetes section for expert insights into the future of diabetes, the need to address clinical inertia, and view a range of Novartis-sponsored webinar topics.
In this section, you can learn about the epidemiology of type 2 diabetes and its links to obesity as well as watch physician and patient thoughts on the future of diabetes.
You can also view a presentation by Dr Edwin B Villhauer who led the team that discovered the first DPP-4 inhibitor, vildagliptin, get a concise view of the ESC guidelines on renin-angiotensin system (RAS) blockers as well as read four recent publications that marked the recent 10th anniversary of the vildagliptin.
Type 2 Diabetes References
Ahmad N, Alfaris N. VLCD for weight loss and remission of type 2 diabetes? Lancet. 2018;392(10155):1306–7.
Diabetes Atlas Committee. Diabetes Atlas. 2nd ed. Belgium: International Diabetes Federation; 2003.
Diabetes Atlas Committee. Diabetes Atlas. 8th ed. International Diabetes Federation; 2017.
Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world – a growing challenge. N Engl J Med. 2007;356:213–21.
Kolb H, Martin S. Environmental/lifestyle factors in the pathogenesis and prevention of type 2 diabetes. BMC Med. 2017;15:131.
Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391(10120):541–51.
World Health Organization. Noncommunicable diseases fact sheet. 2017a. Available at www.who.int/mediacentre/factsheets/fs355/en/ (accessed March 2018).
World Health Organization. Diabetes fact sheet. 2017b. Available at www.who.int/mediacentre/factsheets/fs312/en/ (accessed March 2018).
World Health Organization. Obesity and overweight fact sheet. 2018. Available at www.who.int/mediacentre/factsheets/fs311/en/ (accessed March 2018).
Strain D. Time to do more for diabetes: Clinical inertia and how to beat it. Diabetes Voice. 2014;59:36–9.
Strain WD, Blüher M, Paldánius P. Clinical inertia in individualising care for diabetes: Is there time to do more in type 2 diabetes? Diabetes Ther. 2014b:5:347–54.
Strain ED, Cos X, Hirst M, Vencio S, Mohan V, Vokó Z, et al. Time to do more: Addressing clinical inertia in the management of type 2 diabetes mellitus. Diabetes Res Clin Pract. 2014a;105(3):302–12.
Developed by EPG Health for Medthority in collaboration with Novartis Pharma AG, with content provided by Novartis Pharma AG. The views presented in the videos are those of the presenters and not necessarily those of the industry sponsor, Novartis Pharma AG. Any data on non- Novartis products are based on publicly available information at the time of content update. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the SmPC or product information approved in your local country. Time2DoMore is a trademark owned by Novartis Pharma AG. Following codes supersede any other material reference number appearing on the assets: GLEM/GAL/0072, 75, 79, 84, 99. Diabetes Clinical Trials: Date of preparation August 2020 GLEM/GAL/0115 and December 2020 FUSE code: 19416.